Guggenheim Capital LLC Exact Sciences Corp Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Guggenheim Capital LLC holds 33,256 shares of EXAS stock, worth $1.93 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

33,256

Previous 41,468 19.8%

Holding current value

$1.93 Million

Previous $1.75 Million 29.22%

% of portfolio

0.02%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$42.43 - $70.83 $348,435 - $581,655	-8,212 Reduced 19.8%	33,256 $2.26 Million
Q2 2024 Aug 14, 2024	BUY	$41.33 - $74.26 $248,517 - $446,525	6,013 Added 16.96%	41,468 $1.75 Million
Q1 2024 May 14, 2024	BUY	$56.27 - $73.77 $144,445 - $189,367	2,567 Added 7.81%	35,455 $2.45 Million
Q4 2023 Feb 14, 2024	SELL	$59.06 - $75.72 $45,712 - $58,607	-774 Reduced 2.3%	32,888 $2.43 Million
Q3 2023 Nov 14, 2023	BUY	$65.94 - $99.04 $104,646 - $157,176	1,587 Added 4.95%	33,662 $2.3 Million
Q2 2023 Aug 11, 2023	SELL	$62.68 - $95.05 $475,302 - $720,764	-7,583 Reduced 19.12%	32,075 $3.01 Million
Q1 2023 May 10, 2023	SELL	$47.19 - $70.77 $657,970 - $986,746	-13,943 Reduced 26.01%	39,658 $2.69 Million
Q4 2022 Feb 14, 2023	SELL	$30.35 - $53.15 $273,150 - $478,350	-9,000 Reduced 14.38%	53,601 $2.65 Million
Q3 2022 Nov 14, 2022	SELL	$31.97 - $49.37 $393,167 - $607,152	-12,298 Reduced 16.42%	62,601 $2.03 Million
Q2 2022 Aug 15, 2022	BUY	$35.61 - $76.23 $365,216 - $781,814	10,256 Added 15.87%	74,899 $2.95 Million
Q1 2022 May 16, 2022	SELL	$57.56 - $82.54 $88,354 - $126,698	-1,535 Reduced 2.32%	64,643 $4.52 Million
Q4 2021 Feb 14, 2022	BUY	$72.5 - $100.68 $448,340 - $622,605	6,184 Added 10.31%	66,178 $5.15 Million
Q3 2021 Nov 15, 2021	BUY	$90.24 - $124.05 $367,186 - $504,759	4,069 Added 7.28%	59,994 $5.73 Million
Q2 2021 Aug 13, 2021	BUY	$93.66 - $139.27 $31,188 - $46,376	333 Added 0.6%	55,925 $6.95 Million
Q1 2021 May 13, 2021	BUY	$116.57 - $155.01 $314,855 - $418,682	2,701 Added 5.11%	55,592 $7.33 Million
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $1.3 Million - $1.86 Million	-13,080 Reduced 19.83%	52,891 $7.01 Million
Q3 2020 Nov 13, 2020	SELL	$72.92 - $102.01 $445,832 - $623,689	-6,114 Reduced 8.48%	65,971 $6.73 Million
Q2 2020 Aug 14, 2020	BUY	$55.75 - $92.75 $1.02 Million - $1.7 Million	18,300 Added 34.02%	72,085 $6.27 Million
Q1 2020 Jun 02, 2020	SELL	$37.9 - $104.44 $380,440 - $1.05 Million	-10,038 Reduced 15.73%	53,785 $3.12 Million
Q4 2019 Feb 14, 2020	BUY	$77.66 - $99.74 $1.13 Million - $1.45 Million	14,554 Added 29.54%	63,823 $5.9 Million
Q3 2019 Nov 14, 2019	SELL	$90.37 - $122.49 $130,946 - $177,488	-1,449 Reduced 2.86%	49,269 $4.45 Million
Q2 2019 Aug 14, 2019	SELL	$89.51 - $118.04 $994,366 - $1.31 Million	-11,109 Reduced 17.97%	50,718 $5.99 Million
Q1 2019 May 15, 2019	SELL	$61.98 - $96.5 $583,727 - $908,837	-9,418 Reduced 13.22%	61,827 $5.36 Million
Q4 2018 Feb 14, 2019	SELL	$56.04 - $82.66 $179,159 - $264,264	-3,197 Reduced 4.29%	71,245 $4.5 Million
Q3 2018 Nov 14, 2018	SELL	$48.29 - $80.6 $231,792 - $386,880	-4,800 Reduced 6.06%	74,442 $5.88 Million
Q2 2018 Aug 14, 2018	SELL	$37.84 - $69.96 $1.09 Million - $2.01 Million	-28,765 Reduced 26.63%	79,242 $4.74 Million
Q1 2018 May 15, 2018	SELL	$39.82 - $57.53 $6,132 - $8,859	-154 Reduced 0.14%	108,007 $4.36 Million
Q4 2017 Feb 14, 2018	SELL	$46.49 - $60.51 $1.15 Million - $1.5 Million	-24,782 Reduced 18.64%	108,161 $5.68 Million
Q3 2017 Nov 14, 2017	BUY	$37.05 - $47.12 $4.93 Million - $6.26 Million	132,943	132,943 $6.27 Million

Others Institutions Holding EXAS

# of Institutions

673

Shares Held

162M

Call Options Held

2.58M

Put Options Held

2.19M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.3B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Exact Sciences Corp Transaction History